India’s linguistic diversity presents a persistent challenge for large AI models, a gap the company aims to address by developing more representative training data.
The company’s therapies reprogram pathological tissue states like inflammation toward recovery.
The company’s total funding now stands at $42 million, following a $12 million raise in April 2024.
The company aims to use diverse genomic data and AI solutions to provide actionable intelligence for oncology.
The company plans to hire more than 5,000 employees over the next few years.
The company will focus its new facility on expanding its multi-agentic AI platform for the oncology sector.
The company plans to enhance its code migration AI models and fuel global expansion.
The company established an India AI Lab and a new Cognizant Moment Studio to build upon its existing capabilities.
The new branch is expected to diversify the automotive company’s R&D strategy and attract local software engineering talent.
As a convertible funding round, the final valuation and total amount will be determined later based on the company’s future performance.
We're always looking for news.
